Clinical Trial Update: A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL [Phase 2]

View source ↗

Summary

A Phase II trial is evaluating a four-drug combination (mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide) in relapsed B-cell non-Hodgkin lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Mosunetuzumab (mosunetuzumab)
• Polivy (polatuzumab vedotin)
• Revlimid (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hodgkin Lymphoma, B-Cell Lymphoma | Phase 2 | Status: RECRUITING